Nasdaq adds Moderna stock to the Nasdaq-100 index

Published on 10/05/2026 at 14:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 145.0 million, up 2.00 percent year over year. Moderna stock costs EUR 168.92 on October 5, 2026 after EUR 168.67.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) was trading at EUR 168.92 at Lang & Schwarz on October 5, 2026 at 2:31 p.m. CEST, up 0.15 percent versus the prior close of EUR 168.67. Finanznachrichten reports that Nasdaq announced on October 1, 2026 that Moderna will join the Nasdaq-100 index before market open on October 9, replacing Warner Bros. Discovery. The index decision gives the stock a dated benchmark event while the company continues to absorb heavy development costs.

Index entry sets a date

The Nasdaq-100 inclusion takes effect before market open on October 9, 2026, according to the Nasdaq announcement carried by Finanznachrichten. Moderna will replace Warner Bros. Discovery in the 100-company benchmark, giving the listing a specific index change to track.

The timing matters because the scheduled change is distinct from Moderna's operating results. It places the company inside a major Nasdaq benchmark at the same time that investors are weighing vaccine sales against the oncology pipeline.

Second-quarter loss remains large

Investing.com reported that Moderna generated USD 145.0 million of revenue in the second quarter of 2026, up 2.00 percent from the same period a year earlier. The company also posted a USD 782.0 million net loss, compared with USD 825.0 million in the second quarter of 2025.

The revenue comparison is modest, but the loss comparison shows a narrower deficit. Investing.com also reported adjusted earnings per share of negative USD 1.97 for the second quarter, versus a consensus estimate of negative USD 2.03.

Nasdaq quote stays below yearly high

On the primary NASDAQ listing, Moderna was quoted at USD 190.01 on October 2, 2026 at 4:00 p.m. EDT, with a 52-week range of USD 22.28 to USD 208.90. The company carried a market capitalization of USD 75.4 billion as of October 2, 2026.

The primary-market range is stated in US dollars and is separate from the euro reference quote. Moderna's business profile remains centered on messenger RNA medicines across infectious diseases, oncology and rare diseases, while its latest reported quarter still showed a substantial cash-consuming loss.

Euro quote holds above prior close

At Lang & Schwarz, Moderna was trading at EUR 168.92 on October 5, 2026 at 2:31 p.m. CEST, plus 0.15 percent versus the prior close of EUR 168.67 from October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.